Given the significant incidence of prostate cancer (PC) among Ukrainian men, it is critical to study the state of pharmaceutical support to ensure proper and effective disease management. The analysis of the distribution of 47 drugs by countries of origin, including leaders such as India (29.8 %), Germany (19.1 %) and Ukraine (12.8 %), indicates the uneven geographical impact and variety of types of drugs – from original to generic. The dynamics of prices, which increased by 2–6 % in 2025 compared to previous years, reflect the impact of inflation and imported factors. This context emphasizes the need for a comprehensive study of the pharmaceutical market to support domestic producers and to ensure the availability of therapy.

The aim of the study was to carry out a marketing analysis of drugs registered in the pharmaceutical market of Ukraine as of April – August 2025, which are used for the management of PC, with the subsequent assessment of nomenclature, origin, forms of release, price correlation and pharmacoeconomic aspects.

Materials and methods. The study is based on the State Register of Medicines of Ukraine, the National Cancer Register, information from the web resources Compendium, apteka911.ua, Tabletki.ua and other sites-aggregators, as well as the unified clinical protocol of the Ministry of Health of Ukraine and the International Instruction of the European Association of Urology and National Comprehensive Cancer Network. Methods of information search, comparative, analytical and marketing analysis, correlation, pharmacoeconomic analysis have been applied. To conduct pharmacoeconomic analysis (Cost-Effectiveness Analysis method, Cost-Minimization Analysis method), prices in pharmacy chains for the period April – August 2025 and reimbursement program data were taken into account.

Results. Analysis of 47 oncological drugs for the treatment of PC as of August 2025 revealed India’s leadership (29.8 %, 14 generics), Germany (19.1 %, 9 original and generics) and Ukraine (12.8 %, 6 generics). In total, 68.0 % of drugs are generics, 32.0 % are original, mainly from the United Kingdom and the United States (6.4 %, 3 drugs). Prices increased by 2–6 % in 2025 compared to 2024.

Conclusions. The study confirmed the dominance of generics (68 %) in the PC market in 2025, with India leadership (29.8 %) and a significant contribution of Ukraine (12.8 %), which increases availability. Germany (19.1 %), the United Kingdom and the United States (6.4 %) provide original drugs, but their high cost requires subsidizing. The rise in prices by 2–6 % emphasizes the importance of local production in Ukraine, where 1.19 million cancer patients are registered. EAU and NCCN support the use of analyzed drugs, which indicates their clinical relevance.